EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Autoimmunity in MASLD: Focus on autoantibodies, anti‐apolipoprotein A1 IgG and G protein‐coupled receptors

Sabrina Pagano, Emmanuel Somm, François R Jornayvaz, Nicolas Vuilleumier

European Journal of Clinical Investigation · 2025

DOI: 10.1111/eci.70092 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Clinical Investigation, 2025. Verfasst von Sabrina Pagano und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Laboratory Medicine, Diagnostic Department, Geneva University Hospitals, Geneva, Switzerland. Hauptthemen laut MEDLINE: Autoantibodies, Receptors, G-Protein-Coupled, Non-alcoholic Fatty Liver Disease, Autoimmunity. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 141 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Fondation Ernst et Lucie Schmidheiny, Swiss National Science Foundation, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The increasing prevalence of metabolic dysfunction‐associated steatotic liver disease (MASLD), formerly known as non‐alcoholic fatty liver disease (NAFLD), represents a significant public health concern, as it is closely linked to rising obesity rates and metabolic syndrome, affecting approximately 30% of the global population. In addition, MASLD, along with its more severe form, metabolic dysfunction‐associated steatohepatitis (MASH), increases the risk of cardio‐metabolic diseases and hepatocellular carcinoma. In recent years, multiple G‐protein‐coupled receptors (GPCRs) have been identified as potential therapeutic targets for these disorders. Additionally, autoimmunity is believed to potentially play a role in the development of mechanisms contributing to the pathogenesis of MASLD/MASH. This narrative review examines the diverse autoantibodies associated with the disease, with a particular emphasis on antibodies targeting apolipoprotein A‐1 (AAA‐1) and their relationship with anti‐GPCRs antibodies.

Results

Several autoantibodies have been identified in up to 30% of individuals with MASLD/MASH, both with and without concomitant autoimmune diseases. Among the anti‐GPCR autoantibodies identified in MASLD to date are those targeting the angiotensin II type 1 receptor and the endothelin‐1 type A receptor. While the contribution of this class of autoantibodies to MASLD/NASH remains unclear, AAA‐1 appears to be pathogenic, acting as pro‐steatotic and pro‐inflammatory mediators. Additionally, current data suggest shared functional responses between anti‐GPCR antibodies and AAA1 in cell‐based assays used to detect anti‐GPCR presence.

Conclusion

A better understanding of the role of humoral autoimmunity and the interactions among its various components in the metabolic dysfunction underlying MASLD/MASH has the potential to open new perspectives for early detection and therapeutic interventions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AutoantibodiesReceptors, G-Protein-CoupledNon-alcoholic Fatty Liver DiseaseAutoimmunityApolipoprotein A-IHumansImmunoglobulin GReceptor, Angiotensin, Type 1Receptor, Endothelin A

Stichwörter der Autor:innen

G protein‐coupled receptorsMASHMASLDanti‐GPCRs antibodiesanti‐apolipoprotein A‐1 antibodiesautoimmunity

Substanzen

AutoantibodiesReceptors, G-Protein-CoupledApolipoprotein A-IImmunoglobulin GReceptor, Angiotensin, Type 1Receptor, Endothelin A

Autor:innen und Institutionen

  • Division of Laboratory Medicine, Diagnostic Department, Geneva University Hospitals, Geneva, Switzerland.
  • Department of Medicine, Medical Faculty, Geneva University, Geneva, Switzerland.
  • Service of Endocrinology, Diabetes, Nutrition and Therapeutic Patient Education, Department of in-Ternal Medicine, Geneva University Hospitals, Geneva, Switzerland.
  • Department of Cell Physiology and Metabolism, University of Geneva, Geneva, Switzerland.
  • Diabetes Center of the Faculty of Medicine, University of Geneva, Geneva, Switzerland.

Förderung

  • Fondation Ernst et Lucie Schmidheiny
  • Swiss National Science Foundation
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung

Zitieren

APA

Pagano, S., Somm, E., Jornayvaz, F. R., & Vuilleumier, N. (2025). Autoimmunity in MASLD: Focus on autoantibodies, anti‐apolipoprotein A1 IgG and G protein‐coupled receptors. European Journal of Clinical Investigation. https://doi.org/10.1111/eci.70092

Vancouver

Pagano S, Somm E, Jornayvaz FR, Vuilleumier N. Autoimmunity in MASLD: Focus on autoantibodies, anti‐apolipoprotein A1 IgG and G protein‐coupled receptors. European Journal of Clinical Investigation. 2025. doi:10.1111/eci.70092

BibTeX
@article{Pagano2025,
  author = {Pagano, Sabrina and Somm, Emmanuel and Jornayvaz, François R and Vuilleumier, Nicolas},
  title = {Autoimmunity in MASLD: Focus on autoantibodies, anti‐apolipoprotein A1 IgG and G protein‐coupled receptors},
  journal = {European Journal of Clinical Investigation},
  year = {2025},
  doi = {10.1111/eci.70092}
}
Kostenlos starten →